DexCom, Inc. (NASDAQ:DXCM) Position Reduced by Ownership Capital B.V.

Ownership Capital B.V. trimmed its position in DexCom, Inc. (NASDAQ:DXCM) by 17.6% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 761,810 shares of the medical device company’s stock after selling 162,860 shares during the period. DexCom makes up about 1.6% of Ownership Capital B.V.’s portfolio, making the stock its 21st largest holding. Ownership Capital B.V. owned 0.20% of DexCom worth $51,072,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Canada Pension Plan Investment Board lifted its holdings in shares of DexCom by 189.1% in the second quarter. Canada Pension Plan Investment Board now owns 665,646 shares of the medical device company’s stock valued at $75,471,000 after buying an additional 435,401 shares during the period. Massachusetts Financial Services Co. MA boosted its position in shares of DexCom by 16.9% during the 2nd quarter. Massachusetts Financial Services Co. MA now owns 2,439,033 shares of the medical device company’s stock valued at $276,538,000 after purchasing an additional 353,019 shares in the last quarter. Assenagon Asset Management S.A. grew its stake in shares of DexCom by 53.5% in the 3rd quarter. Assenagon Asset Management S.A. now owns 989,740 shares of the medical device company’s stock worth $66,352,000 after purchasing an additional 345,114 shares during the last quarter. Bellevue Group AG raised its holdings in shares of DexCom by 33.5% in the 1st quarter. Bellevue Group AG now owns 1,221,197 shares of the medical device company’s stock worth $169,380,000 after purchasing an additional 306,604 shares in the last quarter. Finally, Magnetar Financial LLC bought a new stake in shares of DexCom in the 2nd quarter worth approximately $31,793,000. 97.75% of the stock is owned by institutional investors.

DexCom Price Performance

Shares of NASDAQ:DXCM opened at $69.96 on Friday. The business has a fifty day simple moving average of $69.66 and a 200 day simple moving average of $93.70. The company has a current ratio of 2.46, a quick ratio of 2.12 and a debt-to-equity ratio of 1.23. DexCom, Inc. has a 1 year low of $62.34 and a 1 year high of $142.00. The firm has a market cap of $27.33 billion, a price-to-earnings ratio of 41.89, a P/E/G ratio of 2.10 and a beta of 1.17.

Insider Transactions at DexCom

In related news, EVP Sadie Stern sold 426 shares of the business’s stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $69.15, for a total value of $29,457.90. Following the completion of the sale, the executive vice president now owns 75,451 shares of the company’s stock, valued at approximately $5,217,436.65. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In other DexCom news, EVP Sadie Stern sold 426 shares of the business’s stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $69.15, for a total value of $29,457.90. Following the completion of the sale, the executive vice president now directly owns 75,451 shares of the company’s stock, valued at $5,217,436.65. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, COO Jacob Steven Leach sold 746 shares of the firm’s stock in a transaction on Monday, September 9th. The shares were sold at an average price of $69.15, for a total transaction of $51,585.90. Following the transaction, the chief operating officer now owns 264,915 shares in the company, valued at $18,318,872.25. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 0.30% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have issued reports on the stock. Baird R W lowered shares of DexCom from a “strong-buy” rating to a “hold” rating in a research report on Friday, July 26th. Canaccord Genuity Group restated a “buy” rating and issued a $145.00 target price on shares of DexCom in a report on Tuesday, July 23rd. Wells Fargo & Company upped their target price on DexCom from $80.00 to $90.00 and gave the company an “overweight” rating in a report on Friday, October 25th. Stifel Nicolaus lifted their price target on DexCom from $90.00 to $100.00 and gave the stock a “buy” rating in a research note on Friday, August 23rd. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $90.00 price objective on shares of DexCom in a research note on Monday, August 26th. Seven research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $104.59.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.